Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity.
Klara R KleinTrine J AbrahamsenAngelica Cristello SarteauG Caleb AlexanderChristopher G ChuteMelissa A HaendelStephanie S HongHemalkumar B MehtaRichard A MoffittTil StürmerKajsa KvistJohn B Busenull nullPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)
Among adults who tested positive for SARS-CoV-2, premorbid use of either GLP-1RA or SGLT-2i is associated with lower odds of mortality compared to DPP-4i. Furthermore, concomitant use of GLP-1RA and SGLT-2i is linked to lower odds of other severe COVID-19 outcomes, including ER visits, hospitalizations, and mechanical ventilation, compared to SGLT-2i use alone. Graphical abstract available for this article.
Keyphrases
- sars cov
- mechanical ventilation
- rheumatoid arthritis
- coronavirus disease
- respiratory syndrome coronavirus
- disease activity
- acute respiratory distress syndrome
- intensive care unit
- ankylosing spondylitis
- cardiovascular events
- systemic lupus erythematosus
- early onset
- estrogen receptor
- adipose tissue
- risk factors
- cardiovascular disease
- skeletal muscle
- coronary artery disease
- extracorporeal membrane oxygenation
- idiopathic pulmonary fibrosis
- endoplasmic reticulum